Aldeyra Therapeutics, Inc.
NCM: ALDXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Aldeyra Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ALDX Z-Score →About Aldeyra Therapeutics, Inc.
Healthcare
Biotechnology
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
📊 Fundamental Analysis
Aldeyra Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -58.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.78, ALDX currently trades near the bottom of its 52-week range (14%), indicating potential value or weakness (Range: $1.07 - $6.17).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$107.13M
Trailing P/E
--
Forward P/E
-6.91
Beta (5Y)
1.33
52W High
$6.17
52W Low
$1.07
Avg Volume
3.04M
Day High
Day Low